Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Chemopreventive Agent Development
Sponsor
National Cancer Institute (NCI)
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT01077453
This randomized phase I trial studies the side effects and the best dose of letrozole in preventing breast cancer in healthy postmenopausal women at high risk for breast cancer. Chemoprevention is the use of drugs to keep breast cancer from forming or coming back. The use of letrozole may keep cancer from forming in healthy postmenopausal women at high risk for breast cancer.
Intervention
laboratory biomarker analysis, letrozole, quality-of-life assessment
Condition
Healthy, no Evidence of Disease, Lobular Breast Carcinoma in Situ
Investigators
Ana Lopez